Vascular surgery.html

 
ca de en es fr it nl no pl pt ru ro fi sv tr vo


 

Vascular surgery is a specialty of surgery in which diseases of the vascular system, or arteries and veins, are managed by medical therapy, minimally-invasive catheter procedures, and surgical reconstruction. The specialty evolved from general and cardiac surgery. Edwin Wylie of San Francisco was one of the early pioneers in the specialty who developed and fostered advanced training in vascular surgery and pushed for its recognition as a specialty in the United States in the 1960's and 1970's. The vascular surgeon is trained in the diagnosis and management of diseases affecting all parts of the vascular system except that of the heart and brain. Cardiothoracic surgeons manage surgical disease of the heart and its vessels. Neurosurgeons manage surgical disease of the vessels in the brain (eg intracranial aneurysms).

Contents

Breadth of discipline

Training

Previously considered a field within general surgery, it is now considered a specialty in its own right. As a result, there are two pathways for training in the United States. Traditionally, a five year general surgery residency is followed by a 1-2 year (typically 2 years) vascular surgery fellowship. An alternative path is to perform a five or six year vascular surgery residency.

Programs of training are slightly different depending on the region of the world one is in.

Country Standards body Professional representation Minimum Length of training (post intern)
Australia and New Zealand Royal Australasian College of Surgeons Australian & New Zealand Society of Vascular Surgery (ANZSVS) 6 years
United Kingdom Royal College of Surgeons of England, Royal College of Surgeons of Edinburgh Vascular Society of Great Britain and Ireland 8 years
USA Accreditation Council for Graduate Medical Education (ACGME), American Board of Surgery American College of Surgeons

Multiple vascular societies

5 years ( 4 via 5-year integrated Vascular Surgery Residency)1

Surgical procedures

By no means exhaustive, but below are a number of common procedures and indications for vascular surgeons.

Indication/disease Procedure
Abdominal aortic aneurysm Open AAA repair

Endoluminal AAA repair (EVAR)

Carotid stenosis Carotid endarterectomy

Carotid stenting

Varicose veins Vein stripping

Sclerotherapy and Foam sclerotherapy or Laser and radiofrequency vein ablation

Ambulatory phlebectomy

Peripheral arterial occlusive disease Angioplasty with/out Stenting

Bypass surgery Endarterectomy Atherectomy

Acute limb ischaemia Balloon embolectomy

Thrombectomy

Bypass surgery

Aortic dissection Open repair

Thoracic stent graft

Perioperative Guidelines in Vascular Surgery

Notes: Doses SHOULD BE CHECKED against approved local protocols.

Thromboprophylaxis.

- All patients: require below knee TED stockings, Deltaparin (2500 units sc) at 6 pm, and intermittent compression boots in theatre (if pulses exist). - All HIGH RISK patients requires Deltaparin 5000 units sc.

 * High risk patients include: Obese, history of DVT/PE, known thrombophilia, varicose veins, amputees, patients on HRT, bedbound for > 3days; surgery for cancer. 

Postcarotid endarterectomy hypertension - Patient in recovery:

 * Check pain status and missed antihypertensives. 
 * first line: Labetolol slow bolouses of 10 mg every two minutes up to 100 mg. 
 * second line (use for failed first line): Hydralazine 2 mg every 5 minutes up to 10 mg. 
 * third line: GTN infusion 5 ml/hr titrated to BP. Patient remain in level 2/3 care while on GTN infusion. 

- Patient in the Ward: [[BP > 170 mmHg + no Headache/neurologic symptoms]]

 * Patient NOT normally on antihypertensives: 
    - First line: Nifidipine 10 mg repeated after 1 hour if no change in BP. 
    - second line: Bisoprolol 5 mg
    - third line: Ramipril 5mg repeated in 3 hours if required. 
 * Patient IS normally on antihypertensives: 
    - First line: check existing medications. any missed dose? patient can not swallow (pass NGT). 
    - second line: use the ABCD protocol: 
      A = ACE inhibitors  B=Beta blockers  C=Calcium channel blockers  D=Diuretics
      If patient on A: add C
      If patient on C: add A
      If patient on D: add A
      If patient on A+C: add D
      If patient on A+D: add C
      If patient on A+C+D: add B

[[BP > 160 mmHg + Headache/neurologic symptoms]] Immediate action required. Apply non-invasive monitoring. Contact Consultant vascular surgeon in charge. Contact ITU SpR.

   - start 8 mg Dexamethazone IV.
   - First line: Labetolol: 10 mg slowly every 2 minutes up to 100 mg. 
   - Second line: Hydralazine: 2 mg slowly every 5 minutes up to 10 mg. 
   - Third line: GTN.

Major Trials in Vascular Surgery

- Edinburgh Artery Study. *Highwire results for Edinburgh Artery Study

- Netherland Vascular Study.2

- Framingham heart study. Highwire results for Framingham heart Study

- MASS Trial. – the Multicentre Aneurysm Screening Study (MASS) trial. Four centres (about 7000 men); screening (and treatment) vs. control group. AAA-related mortality in the screening arm reduced by about 40%; emergency ruptured AAA reducted by about 70%; disruption to elective work was reduced; and better management of risk factors and ITU/HDU beds. The overall survival benefits remain difficult to estimate, nevertheless, screening for AAA is recommended [level of recommendation: B].345

- UK Small Aneurysm Trial: 1090 patients; AAA 4-5.5 cm; Immediate surgery vs. ultrasound survillence (and treatement for rapid expansion or AAA >5.5); 30-day mortality after elective AAA repair is 5.8%. No difference in survival.6

- ADAM VA Cooperative Group Trial. 32697 patients screened; Age 50-79; AAA 4.0-5.4 cm; similar conclusion to Uk Small Aneurysm Trial.7

- Joint Vascular Resaerch Group Trial. 284 patients; Study the relationship between intraoperative intravenous heparinisation, blood loss during surgery and thrombotic complications. Conclusion: Intraoperative heparin, given before aortic cross clamping, is an important prophylaxic against perioperative MI in aortic aneurysm surgery.8

- HOPE (Heart Outcomes Prevention Evaluation) study - 4046 patients with PAD. In this subgroup, there was a 22% risk reduction in patients randomized to ramipril compared with placebo,which was independent of lowering of blood pressure.9

References

  1. ^ VascularWeb: New Vascular Surgery Training Paradigms
  2. ^ Hooi JD, Kester AD, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA (Apr 2001). "Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study". Am J Epidemiol. 153 (7): 666–72. doi:10.1093/aje/153.7.666. PMID 11282794, http://aje.oxfordjournals.org/cgi/content/abstract/153/7/666. 
  3. ^ VSGBI. Position statement for AAA screening 2004
  4. ^ Ashton HA, Buxton MJ, Day NE, et al (Nov 2002). "The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial". Lancet 360 (9345): 1531–9. doi:10.1016/S0140-6736(02)11522-4. PMID 12443589, http://linkinghub.elsevier.com/retrieve/pii/S0140673602115224. 
  5. ^ Fleming C, Whitlock EP, Beil TL, Lederle FA (01 Feb 2005). "Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force". Ann Intern Med. 142 (3): 203–11. PMID 15684209, http://www.annals.org/cgi/content/abstract/142/3/203. 
  6. ^ "Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants". Lancet 352 (9141): 1649–55. Nov 1998. doi:10.1016/S0140-6736(98)10137-X. PMID 9853436, http://linkinghub.elsevier.com/retrieve/pii/S014067369810137X. 
  7. ^ Lederle FA, Wilson SE, Johnson GR, et al (Aug 1994). "Design of the abdominal aortic Aneurysm Detection and Management Study. ADAM VA Cooperative Study Group". J Vasc Surg. 20 (2): 296–303. PMID 8040955. 
  8. ^ Thompson JF, Mullee MA, Bell PR, et al (Jul 1996). "Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study". Eur J Vasc Endovasc Surg 12 (1): 86–90. doi:10.1016/S1078-5884(96)80281-4. PMID 8696904. 
  9. ^ Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (Jan 2000). "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators". N Engl J Med. 342 (3): 145–53. doi:10.1056/NEJM200001203420301. PMID 10639539, http://content.nejm.org/cgi/pmidlookup?view=short&pmid=10639539&promo=ONFLNS19. 

External links

zasłony • Skuteczne Pozycjonowanie Google • wyniki duży lotek duży lotek duży lotek wyniki • anteny UMTSkartki okolicznoscioweGrzybyGrzybyGrzybyGrzybyGrzybyGrzybyGrzybyGrzybyHoteleHotele All Right Reserved © 2007, Designed by Stylish Blog.